An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease
- 4 August 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (643)
- https://doi.org/10.1126/scisignal.aay3258
Abstract
Anti–tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with patient pretreatment transcriptomic data to identify molecular features discernable in the mouse data that are predictive of patient response to therapy. Interrogating the TransComp-R models revealed activated integrin pathway signaling in patients with anti–TNF-resistant colonic Crohn’s disease (cCD) and ulcerative colitis (UC). As a step toward validation, we performed single-cell RNA sequencing (scRNA-seq) on biopsies from a patient with cCD and analyzed publicly available immune cell proteomics data to characterize the immune and intestinal cell types contributing to anti-TNF resistance. We found that ITGA1 was expressed in T cells and that interactions between these cells and intestinal cell types were associated with resistance to anti-TNF therapy. We experimentally showed that the α1 integrin subunit mediated the effectiveness of anti-TNF therapy in human immune cells. Thus, TransComp-R identified an integrin signaling mechanism with potential therapeutic implications for overcoming anti-TNF therapy resistance. We suggest that TransComp-R is a generalizable framework for addressing species, molecular, and phenotypic discrepancies between model systems and patients to translationally deliver relevant biological insights.Funding Information
- National Institutes of Health (KL2TR002245)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103831)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK058404)
- Army Research Office (ICB W911NF-19-2-0026)
- Leona M. and Harry B. Helmsley Charitable Trust (Gut Cell Atlas G-1903-03793)
- Boehringer Ingelheim (Research Beyond Borders SHINE)
This publication has 57 references indexed in Scilit:
- Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab TreatmentPLOS ONE, 2009
- Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitisGut, 2009
- Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot studyClinical Biochemistry, 2008
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- PANTHER: A Library of Protein Families and Subfamilies Indexed by FunctionGenome Research, 2003
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Importance of Innate Immunity and Collagen Binding Integrin α1β1 in TNBS-Induced ColitisImmunity, 2002
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- MEKK1 Binds Raf-1 and the ERK2 Cascade ComponentsOnline Journal of Public Health Informatics, 2000
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000